MYCN and neuroblastoma: Half of all NB patients present a high-risk (HR) disease associated with the presence of aggressive genetic features (MYCN amplification, recurrent segmental chromosome aberrations including losses of chromosome 1p, 3p, 4p, 11q and gains of 1q, 2p, 17q) that together with age and stage are currently employed to define the risk level and treatment burden.